中山康方生物医药有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Akeso releases promising data of Ivonescimab (PD-1/VEGF BsAbs, AK112) for advanced NSCLC at ASCO 2022 2022-06-06 09:00
Akeso announces oral presentation featuring promising clinical data of Cadonilimab (PD-1/CTLA-4 BsAbs, AK104) for the first-line treatment of R/M cervical cancer at ASCO 2022 2022-06-06 09:00
Akeso releases promising data of Ivonescimab (PD-1/VEGF BsAbs, AK112) combined with chemotherapy in advanced NSCLC at ASCO 2022 2022-06-06 09:00
Akeso Publishes Preclinical Results of PD-1/LAG-3 Bi-specific Antibody（AK129）at the American Association for Cancer Research (AACR) 2022 Annual Meeting 2022-04-14 15:39
Akeso Publishes Preclinical Results of PD-1/CD73 Bi-specific Antibody（AK131）at the American Association for Cancer Research (AACR) 2022 Annual Meeting 2022-04-14 15:05
Akeso Publishes Preclinical Results of TIGIT monoclonal antibody（AK127）at the American Association for Cancer Research (AACR) 2022 Annual Meeting 2022-04-14 14:54
Akeso Reported 2021 Annual Results 2022-04-01 13:44
Akeso Announces IND Approval from China NMPA for Phase II Clinical Trial of Cadonilimab in Combination with Docetaxel to Treat NSCLC 2022-03-08 11:49
Akeso Announces Clinical Trial Collaboration with Chipscreen Biosciences to Evaluate Cadonilimab in Combination with Chiauranib for Extensive-Stage Small-Cell Lung Cancer 2022-03-03 01:34
AKESO'S NGF MONOCLONAL ANTIBODY (AK115) APPROVED TO INITIATE CLINICAL TRIAL IN PAIN (INCLUDING CANCER PAIN) 2022-02-10 17:00
AKESO'S LIGUFALIMAB AND IVONESCIMAB OBTAINED APPROVAL TO INITIATE A PHASE II TRIAL 2022-01-31 10:14
AKESO DOSES FIRST PATIENT IN THE PHASE III TRIAL OF IVONESCIMAB COMBINED WITH CHEMOTHERAPY IN EGFR-TKI RESISTANT EGFR MUTATION ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER 2022-01-31 09:51
Akeso's AK117 (CD47 monoclonal antibody) in Combination with AK112 (PD-1/VEGF bi-specific antibody) to Initiate a Phase Ib/II Clinical Trial with or without Chemotherapy for the Treatment of Advanced Malignant Tumors 2022-01-18 20:44
AKESO'S CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY) COMBINED WITH IVONESCIMAB (PD-1/VEGF BI-SPECIFIC ANTIBODY) COMBINED WITH OR WITHOUT CHEMOTHERAPY OBTAINED APPROVAL TO INITIATE A PHASE Ib/II CLINICAL TRIAL FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER 2022-01-06 19:00
AKESO'S CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY) COMBINED WITH CONCURRENT CHEMORADIOTHERAPY OBTAINED APPROVAL TO INITIATE A PHASE III CLINICAL TRIAL FOR THE TREATMENT OF LOCALLY ADVANCED CERVICAL CANCER 2022-01-04 10:00
Akeso's IL-17A MONOCLONAL ANTIBODY (GUMOKIMAB) COMPLETION OF PATIENT ENROLLMENT IN PHASE II CLINICAL TRIAL FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS 2021-12-28 12:30
Akeso's PCSK9 MONOCLONAL ANTIBODY (EBRONUCIMAB) EARLY COMPLETION OF PATIENT ENROLLMENT IN A PHASE III CLINICAL TRIAL FOR PRIMARY HYPERCHOLESTEROLEMIA AND MIXED HYPERLIPIDEMIA 2021-12-23 12:42
Akeso Announces Launch of U.S. Investigator-Initiated Study of Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) 2021-12-07 08:20
PD-1/VEGF Bi-Specific Antibody (AK112) Obtained Approval to Initiate a Phase II Clinical Trial for Monotherapy or Combined Chemotherapy Neoadjuvant/Adjuvant Therapy of Resectable Non-Small Cell Lung Cancer 2021-11-02 11:53
Akeso is rapidly advancing the clinical study of the PD-1/CTLA-4 bispecific antibody Cadonilimab combined with TIGIT monoclonal antibody for the teratment of solid tumors 2021-10-22 09:50
1 2 3 4